Digital Oral Presentation Session 9 – New therapies

  • 17:20 - 18:20 Digital Oral Presentation Session 9 – New therapies
    Chairs:
    Jean-Frédéric Colombel, New York, United States
    Joana Torres, Lisbon, Portugal
      17:20-17:26 DOP073: Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided Ulcerative Colitis patients with Moderate-to-Severe disease


    Atreya, R.
    1, Kühbacher, T.2,3, Waldner, M.J.1, Hirschmann, S.1, Drvarov, O.2, Abu Hashem, R.2, Maaser, C.4, Kucharzik, T.4, Dinter, J.5, Schramm, C.5, Mertens, J.5, Holler, B.6, Mössner, J.6, Suzuki, K.7, Yokoyama, J.7, Terai, S.7, Yoneyama, H.8, Asakura, H.7, Hibi, T.9, Neurath, M.F.1


    1Friedrich-Alexander University Erlangen-Nürnberg, Department of Medicine I, Erlangen, Germany, 2Asklepios Westklinikum, Department of Internal Medicine/Gastroenterology, Hamburg, Germany, 3Christian Albrechts University Kiel, Department of Internal Medicine/Gastroenterology, Kiel, Germany, 4Klinikum Lüneburg, Klinik für Allgemeine Innere Medizin und Gastroenterologie, Lüneburg, Germany, 5Uniklinik Köln, Klinik für Gastroenterologie und Hepatologie, Köln, Germany, 6Universitätsklinikum Leipzig, Klinik und Poliklinik für Gastroenterologie und Rheumatologie, Leipzig, Germany, 7Niigata University Medical and Dental Hospital, Niigata, Japan, 8Stelic Institute & Co., Tokyo, Japan, 9Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan
      17:26-17:32 DOP074: Pharmacokinetics and exposure-response of tofacitinib in a Phase 3 maintenance study in Ulcerative Colitis patients


    Mukherjee, A.
    1, D'Haens, G.R.2, Sandborn, W.J.3, Tsuchiwata, S.4, Vong, C.5, Deng, C.6, Xie, R.6, Hazra, A.1, Martin, S.W.5, Friedman, G.7, Niezychowski, W.7, Su, C.7


    1Pfizer Inc, Groton, CT, United States, 2Department of Gastroenterology, Academic Medical Centre, Amsterdam, Netherlands, 3Division of Gastroenterology, University of California, San Diego, La Jolla, CA, United States, 4Pfizer Japan Inc, Tokyo, Japan, 5Pfizer Inc, Cambridge, MA, United States, 6Pfizer Inc, Shanghai, China, 7Pfizer Inc, Collegeville, PA, United States
      17:32-17:38 DOP075: Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: Subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohn's Disease


    D'Haens, G.1, Schreiber, S.2, Petryka, R.3, Kuehbacher, T.4, Hebuterne, X.5, Roblin, X.6, Klopocka, M.7, Goldis, A.8, Wisniewska-Jarosinska, M.9, Baranovsky, A.10, Sike, R.11, Stoyanova, K.12, Meuleners, L.13, Tasset, C.13, Van der Aa, A.13, Harrison, P.13, Vermeire, S.14


    1Academic Medical Center (AMC), Department of Gastroenterology, Amsterdam, Netherlands, 2University Medical Center Schleswig-Holstein Kiel, Department of Internal Medicine I, Kiel, Germany, 3Vivamed, Warsaw, Poland, 4Asklepios Hospital West Hamburg, Department of Gastroenterology, Hamburg, Germany, 5CHU Nice Hopital l'Archet, Department of Gastroenterology and Nutrition, Nice Cedex 3, France, 6North Hospital, Department of Gastroenterology, Saint Priez en Jarez, France, 7NC University in Toruń, Collegium Medicum, Bydgoszcz, Poland, 8Dr. Goldis Center for Gastroenterology, Ltd., Timisoara, Romania, 9Santa LLC, Santa Familia Research, Prevention and Treatment Centre, Lodz, Poland, 10City Clinical Hospital #31, St. Petersburg, Russian Federation, 11Szent Margit Hospital, Budapest, Hungary, 12PSI Pharma Support EOOD, Sofia, Bulgaria, 13Galapagos NV, Mechelen, Belgium, 14University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium
      17:38-17:44 DOP076: A Phase 2B, multicenter, randomized, placebo-controlled dose-ranging trial of peficitinab, an OralL JAK Inhibitor, in patients with moderately to severely active Ulcerative Colitis

    Sands, B.
    1, Sandborn, W.2, Feagan, B.G.3, Lichtenstein, G.4, Zhang, H.5, Szapary, P.5, Panes, J.6, Vermeire, S.7, O’Brien, C.5, Dewey, J.5, Yang, Z.5, Johanns, J.5, Strauss, R.5, Marano, C.5


    1Icahn School of Medicine at Mt Sinai, New York, United States, 2University of California San Diego, La Jolla, United States, 3Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ont,, Canada, 4University of Pennsylvania, Philadelphia, United States, 5Janssen Research & Development, LLC, Spring House, United States, 6Hospital Clinic Barcelona, IDIBAPS, CIVERehd, Barcelona, Spain, 7Uz Leuven,Campus Gasthuisberg, Leuven, Belgium
      17:44-17:50 DOP077: Immunomodulatory effects of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator

    Lee, S.D.
    1, Christopher, R.2, Trokan, L.2, Lassen, C.2, Adams, J.2, Chiorean, M.3


    1University of Washington Medical Center, Seattle, United States, 2Arena Pharmaceuticals, Inc., San Diego, United States, 3Virginia Mason, Digestive Disease Institute, Seattle, United States
      17:50-17:56 DOP078: Pharmacology and safety of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator

    Kühbacher, T.
    1, Christopher, R.2, Trokan, L.2, Lassen, C.2, Adams, J.2, Peyrin-Biroulet, L.3


    1Asklepios Westklinikum Hamburg and Christian Albrechts University, Department of Internal Medicine/Gastroenterology, Kiel, Germany, 2Arena Pharmaceuticals, Inc., San Diego, United States, 3Nancy University Hospital and Lorraine University, Department of Gastroenterology, Nancy, France
       17:56-18:02 DOP079: The role of intestinal transplant in patients with complicated Inflammatory Bowel Disease (IBD): The Cambridge experience

    Yeap, S.P.
    1, Sharkey, L.M.1, Woodward, J.M.1, Massey, D.C.1, Middleton, S.J.1, Russell, N.K.2, Butler, A.J.2


    1Addenbrooke's Hospital, Gastroenterology, Cambridge, United Kingdom, 2Addenbrooke's Hospital, Transplant Surgery, Cambridge, United Kingdom
       18:02-18:08 DOP080: Low viral richness at baseline in Ulcerative Colitis patients associated with faecal microbiota transplantation success


    Conceição-Neto, N.1
    , Deboutte, W.1, Dierckx, T.1, Machiels, K.2, Wang, J.1,3, Yinda, C.1, Maes, P.1, Van Ranst, M.1, Joossens, M.1,3, Raes, J.1,3, Vermeire, S.2, Matthijnssens, J.1


    1KU Leuven, Rega Institute, Department of Microbiology and Immunology, Leuven, Belgium, 2KU Leuven, TARGID, Department of Translational Research Centre for GastroIntestinal Disorders (TARGID), Leuven, Belgium, 3VIB, Center for the Biology of Disease, Leuven, Belgium
       18:08-18:14 DOP081: Glycosylation of T cells: A novel targeted-specific therapeutic strategy in IBD

    M. Dias, A.1,2
    , Correia, A.3, Pereira, M.1, R. Almeida, C.4, Alves, I.1, Lima, M.5,6, Marcos-Pinto, R.2,7,8, A. Reis, C.1,2,9, Vilanova, M.2,3, Lago, P.8, S. Pinho, S.1,9


    1Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) & i3S – Instituto de Investigação e Inovação em Saúde, Glycobiology in Cancer, Porto, Portugal, 2Institute of Biomedical Sciences of Abel Salazar (ICBAS), University of Porto, Porto, Portugal, 3Instituto de Investigação e Inovação em Saude (I3S)/Institute for Molecular and Cell Biology (IBMC), Immunobiology Group, Porto, Portugal, 4Instituto de Investigação e Inovação em Saude (I3S)/ Institute of Biomedical Engineering (INEB), NEWTherapies Group, University of Porto, Porto, Portugal, 5Centro Hospitalar do Porto , Multidisciplinary Unit for Biomedical Research (UMIB), Porto, Portugal, 6Centro Hospitalar do Porto, Hematology Department, Porto, Portugal, 7Medical Faculty, Centre for Research in HealthTechnologies and Information Systems (CINTESIS), Porto, Portugal, 8Centro Hospitalar do Porto, Department of Gastroenterology, Porto, Portugal, 9University of Porto, Medical Faculty, Porto, Portugal